Targeting the distal lung in asthma: Do inhaled corticosteroids treat all areas of inflammation?

Treatments in Respiratory Medicine

Volumn 4, Issue 4, 2005, Pages 223-229

  Sutherland, E R ^a   Martin, Richard J ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BRONCHODILATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; CORTICOSTEROID; FLUNISOLIDE; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; IPRATROPIUM BROMIDE; ISOPRENALINE; TRIAMCINOLONE ACETONIDE;

AIRWAY; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; DEVICE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; DRY POWDER; HISTOLOGY; HUMAN; LUNG ALVEOLUS; MEDICAL ASSESSMENT; METERED DOSE INHALER; NOCTURNAL ASTHMA; PNEUMONIA; POWDER INHALER; PRIORITY JOURNAL; RADIOGRAPHY; REVIEW;

ADMINISTRATION, INHALATION; AIRWAY RESISTANCE; ASTHMA; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; LUNG; METERED DOSE INHALERS; PARTICLE SIZE; PULMONARY ALVEOLI;

EID: 24344433829     PISSN: 11763450     EISSN: None     Source Type: Journal    
DOI: 10.2165/00151829-200504040-00001     Document Type: Review

References (29)

1. Guidelines for the diagnosis and management of asthma. National Heart, Lung and Blood Institute; Bethesda (MD) 1997. Report No.: 97-4051
2. Van Vyve T, Chanez P, Lacoste JY, et al. Comparison between bronchial and alveolar samples of bronchoalveolar lavage fluid in asthma. Chest 1992; 102: 356-61
3. Vignola AM, Chanez P, Campbell AM, et al. Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med 1998; 157: 403-9
4. Howarth P. Small airway inflammation and asthma. Int J Clin Pract Suppl 1998; 96: 15-22
5. Carroll N, Elliot J, Morton A, et al. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993; 147: 405-10
6. Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Respir J 1997; 10: 292-300
7. Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997; 100: 44-51
8. Haley KJ, Sunday ME, Wiggs BR, et al. Inflammatory cell distribution within and along asthmatic airways. Am J Respir Crit Care Med 1998; 158: 565-72
9. Kraft M, Djukanovic R, Wilson S, et al. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154: 1505-10
10. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142: 434-57
11. Kraft M, Martin RJ, Wilson S, et al. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med 1999; 159: 228-34
12. King GG, Muller NL, Pare PD. Evaluation of airways in obstructive pulmonary disease using high-resolution computed tomography. Am J Respir Crit Care Med 1999; 159: 992-1004
13. Okazawa M, Muller N, McNamara AE, et al. Human airway narrowing measured using high resolution computed tomography. Am J Respir Crit Care Med 1996; 154: 1557-62
14. Goldin JG, McNitt-Gray MF, Sorenson SM, et al. Airway hyperreactivity: assessment with helical thin-section CT. Radiology 1998; 208: 321-9
15. Wagner EM, Liu MC, Weinmann GG, et al. Peripheral lung resistance in normal and asthmatic subjects. Am Rev Respir Dis 1990; 141: 584-8
16. Irvin CG, Pak J, Martin RJ. Airway-parenchyma uncoupling in nocturnal asthma. Am J Respir Crit Care Med 2000; 161: 50-6
17. Kuhn RJ. Formulation of aerosolized therapeutics. Chest 2001; 120: 94S-8S
18. Patel P, Mukai D, Wilson AF. Dose-response effects of two sizes of monodisperse isoproterenol in mild asthma. Am Rev Respir Dis 1990; 141: 357-60
19. Zanen P, Go LT, Lammers JW. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 1996; 51: 977-80
20. Montreal Protocol. The Montreal Protocol on substances that deplete the ozone layer. In: Final Act (Nairobi: UNEP, 1987). Fed Regist 1994, 98
21. Anderson PJ. Delivery options and devices for aerosolized therapeutics. Chest 2001; 120: 89S-93S
22. Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol 2002; 109: S447-60
23. Laube BL. In vivo measurements of aerosol dose and distribution: clinical relevance. J Aerosol Med 1996; 9 Suppl. 1: S77-91
24. Leach CL. Enhanced drug delivery through reformulating MDIs with HFA propellants: drug deposition and its effect on preclinical and clinical programs. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V proceedings. Buffalo Grove (IL): Interpharm Press, 1996: 133-144
25. Vanden Burgt JA, Busse WW, Martin RJ, et al. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 2000; 106: 1209-26
26. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12: 1346-53
27. Gross G, Thompson PJ, Chervinsky P, et al. Hydrofluoroalkane-134a beclomethasone dipropionate, 400μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800μg, for the treatment of moderate asthma. Chest 1999; 115: 343-51
28. Corren J, Nelson H, Greos LS, et al. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. Ann Allergy Asthma Immunol 2001; 87: 405-11
29. Goldin JG, Tashkin DP, Kleerup EC, et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 1999; 104: S258-67